found Documents: 747

Announcements & Press Releases, Oncology / Immunology | 13 Jul 2021

First Commercial Sale of ORPATHYS® in China Triggering a US$25 million Milestone Payment from AstraZeneca

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, July 13, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces the first commercial sale in China of ORPATHYS® (savolitinib), HUTCHMED’s oral, potent, and high

HKEX - Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Group | 12 Jul 2021

HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering

2 items

Hong Kong, Shanghai, & Florham Park, NJ — Monday, July 12, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM, HKEX:13) today announces the full exercise of the over-allotment option of the Global Offering. Th

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 7 Jul 2021

Monthly Return

1 item

First Commercial Sale of ORPATHYS® in China Triggering a US$25 million Milestone Payment from AstraZeneca

HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering

Monthly Return

HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL-295 in Patients with Advanced Solid Tumors in China

TR-1: Standard form for notification of major holdings

HUTCHMED to Announce 2021 Half-Year Financial Results

U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

Total Voting Rights

Holdings in Company

HUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong Kong

Blocklisting Six Monthly Return

List of Directors and Their Roles and Functions

ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS

HUTCHMED Announces Pricing of Global Offering

HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations

HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancreatic Neuroendocrine Tumors

Disclosure Update

HUTCHMED Launches Hong Kong Initial Public Offering

HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program

Save the date: HUTCHMED to Host Company Update on R&D, Commercial and ASCO Data For Analysts and Investors

HUTCHMED to Attend Upcoming Investor Conferences

Change of Company Name

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

HUTCHMED Initiates Phase II Registration Study of HMPL-689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in China

Results of Annual General Meeting

Vesting of awards under the Long Term Incentive Plan

Notification of Dilution of Voting Rights

HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia

Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme

HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological Malignancies

2020 Annual Report and Notice of Annual General Meeting

HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million

HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors

Vesting of awards under the Long Term Incentive Plan

Chi-Med becomes HUTCHMED

Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity

Chi-Med to Announce 2020 Final Results

Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC

Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases

Blocklisting Six Monthly Return

Total Voting Rights

Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors

Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

Chi-Med to Present at the 39th Annual JP Morgan Healthcare Conference

Grant of Share Options under Share Option Scheme

Chi-Med Hosts Ground-breaking Ceremony for a Large-Scale Manufacturing Plant in Zhangjiang, Shanghai

Total Voting Rights

Notification of Dilution of Voting Rights

Chi-Med Announces US$100 Million Equity Investment by CPP Investments

Chi-Med Highlights HMPL-689 Clinical Data to be Presented at the 62nd ASH Annual Meeting